SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HTDS - Hard To Treat Diseases
HTDS 0.000001000-95.0%May 28 12:33 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: jmhollen6/17/2005 1:02:13 PM
   of 271
 
Hard To Treat Diseases, Incorporated Announces Court's Decision Pending - 6/17/2005 12:38:09 PM

DELRAY BEACH, Fla., Jun 17, 2005 (PRIMEZONE via COMTEX) -- Hard To Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that the Court's decision on the trial of the Company's claims is pending.

The presentation of evidence and legal arguments concluded on June 15th and as indicated on the Court's website:

"DECISION PENDING: Hard to Treat Diseases, Inc. v. Shinn et al., 04-800010. The trial has concluded and the court has granted the parties an additional ten days to submit proposed findings of fact and conclusions of law. The court's decision will be filed with the clerk of court shortly thereafter and a precis of the decision will be published on this website. Persons desiring a copy of the decision should make appropriate arrangements with the clerk of court."

The Court's decision will be available on their website: us.geocities.com

Upon publication, a complete copy of the Court's decision can be viewed on the Company's website at: www.htdsotc.com

The Company recognizes that the courts are open to the public and does not in any way intend to suggest otherwise, but the Company does request that interested persons be respectful of the Court's time and direct questions to the Clerk of the Courts, as identified in the Court's announcement.

HTTD's shareholders and investors will be kept informed of all public developments as they occur regarding the Company's matters. In order to ensure the confidentiality of the Company's business and legal strategies and not to undermine the authority of the Court, certain specific information may not be immediately available. Once such information can be revealed, it will be publicly disclosed to all shareholders.

HTTD is currently involved in litigation regarding the rights to Tubercin(r). Additional information and details regarding the litigation can be viewed at our website at: www.htdsotc.com

SOURCE: Hard to Treat Diseases, Inc.
Hard To Treat Diseases, Incorporated
Colm J. King, CEO
(561) 278-7856
www.htdsotc.com
,
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext